Clinical and experimental studies have demonstrated Hippo pathway activation/YAP inhibition in various types of heart disease including DCM, diabetic cardiomyopathy, arrhythmogenic cardiomyopathy, myocardial infarction, and HF 17, 34-36. Here, YAP1 is linked to diabetic cardiomyopathy.